Summary
A total of 16 patients with recurrent epithelial ovarian cancer were treated with sulofenur (LY 186641), a novel oral sulfonylurea. All subjects had received previous chemotherapy. Anaemia occurred in all 16 patients, 14 of whom required a blood transfusion, and 2/16 patients received methylene blue for breathlessness due to methaemaglobinaemia. Treatment was discontinued in 2/16 cases due to rising liver enzyme values, which reverted to normal on cessation of the drug. There was no nausea or alopecia. Only two minor responses were seen. Plasma drug levels were insufficient to result in antitumour activity as extrapolated from animal data. Further studies that attempt to increase the bioavailability and improve the therapeutic index are warranted.
This is a preview of subscription content, log in via an institution to check access.
References
Armand JP, Recondo G, Gouyette A, Belerahdek M, Bonnay M, Chabot G, L'Homme C (1989) Phase I and pharmacokinetic study of LY 186641 administered daily for 2 weeks every 21 days. Proceedings, 6th NCI EORTC Symposium on New Drugs in Cancer Chemotherapy, October, Amsterdam
Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59:650–653
Gore M, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207–211
Grindey GB (1988) Identification of diarylsulfonylureas as novel anticancer drugs. Proc Am Assoc Cancer Res 29:535
Houghton PJ, Houghton JA, Myers I, Cheshire P, Howbert JS, Grindey GB (1989) Evaluation ofN-(5-indanylsulfonyl)-N′-4-chlorophenyl-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 25:84–87
Houghton PJ, Bailey FC, Germain GS, Grindey GB, Howbert JS, Houghton JA (1990) Studies on the cellular pharmacology ofN-4-(methylphenylsulfonyl)-N′-(4-chlorophenyl)-urea. Biochem Pharmacol 39:1187–1192
Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, Salmon SE (1989) Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J Clin Oncol 7:1733–1740
Witlshaw E (1985) Ovarian trials at the Royal Marsden. Cancer Treat Rev 12:67–71
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
O'Brien, M.E., Hardy, J., Tan, S. et al. A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer. Cancer Chemother. Pharmacol. 30, 245–248 (1992). https://doi.org/10.1007/BF00686324
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00686324